» Articles » PMID: 32269293

A Comparative Study of Extracellular Vesicle-associated and Cell-free DNA and RNA for HPV Detection in Oropharyngeal Squamous Cell Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2020 Apr 10
PMID 32269293
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study compares the detection sensitivity of two separate liquid biopsy sources, cell-free (cf) DNA/RNA and extracellular vesicle (EV)-associated DNA/RNA (EV-DNA/RNA), to identify circulating Human Papilloma Virus (HPV) DNA/RNA in plasma obtained from patients with oropharyngeal squamous cell carcinoma (OPCSCC). We also report on the longitudinal changes observed in HPV-DNA levels in response to treatment.

Experimental Design: A prospective study was conducted that included 22 patients with locally advanced disease and six patients with metastatic OPCSCC. Twenty-three patients had HPV-related OPCSCC defined by p16 immunohistochemistry. Levels of circulating HPV-DNA and HPV-RNA from plasma-derived cf-DNA/RNA and EV-DNA/RNA were quantified using digital droplet PCR.

Results: Circulating HPV-DNA was detected with higher sensitivity in cf-DNA compared to EV-DNA at 91% vs. 42% (p = <0.001). Similarly, circulating tumoral HPV-RNA was detected at a higher sensitivity in cf-RNA compared to EV-RNA, at 83% vs. 50% (p = 0.0019). In the locally advanced cohort, 100% (n = 16) of HPV-OPCSCC patients demonstrated a reduction in circulating HPV-DNA levels in cf-DNA following curative treatment, with 81% of patients demonstrating complete clearance to undetectable levels. However, in metastatic HPV-OPCSCC patients (n = 4), HPV-DNA levels did not correlate with treatment response.

Conclusion: Our study demonstrates that although HPV-DNA/RNA can be detected in EV associated DNA/RNA, cf-DNA/RNA is the more sensitive liquid biopsy medium. As circulating HPV-DNA levels were found to only correlate with treatment response in the locally advanced but not metastatic setting in our small cohort of patients, the use of HPV-DNA as a dynamic biomarker to monitor treatment response requires further evaluation.

Citing Articles

Circulating HPV Tumor DNA and Molecular Residual Disease in HPV-Positive Oropharyngeal Cancers: A Scoping Review.

Migliorelli A, Ciorba A, Manuelli M, Stomeo F, Pelucchi S, Bianchini C Diagnostics (Basel). 2024; 14(23).

PMID: 39682570 PMC: 11640492. DOI: 10.3390/diagnostics14232662.


The detection, biological function, and liquid biopsy application of extracellular vesicle-associated DNA.

Guo S, Wang X, Shan D, Xiao Y, Ju L, Zhang Y Biomark Res. 2024; 12(1):123.

PMID: 39402599 PMC: 11476736. DOI: 10.1186/s40364-024-00661-2.


The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer.

Krsek A, Baticic L, Braut T, Sotosek V Biomolecules. 2024; 14(8).

PMID: 39199313 PMC: 11352962. DOI: 10.3390/biom14080925.


Quantification of human papillomavirus cell-free DNA from low-volume blood plasma samples by digital PCR.

Rosing F, Meier M, Schroeder L, Laban S, Hoffmann T, Kaufmann A Microbiol Spectr. 2024; 12(7):e0002424.

PMID: 38829114 PMC: 11218464. DOI: 10.1128/spectrum.00024-24.


Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study.

Li G, Wang H, Zhong J, Bai Y, Chen W, Jiang K Br J Cancer. 2024; 130(6):925-933.

PMID: 38238428 PMC: 10951262. DOI: 10.1038/s41416-024-02575-0.